SpringerLink
Log in

Hepatitis C Management in Patients with Hepatitis C and HIV Co-infection

  • Hepatitis C (J Ahn, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Co-infection with HIV and hepatitis C (HCV) is common due to similar risk factors. Twenty-five to thirty percent of HIV+ patients are co-infected with HCV. HCV infection in HIV+ patients is associated with higher rates of fibrosis, progression to cirrhosis and decompensated liver disease, and liver-related mortality. The ultimate HCV treatment goal is viral eradication, or sustained virologic response (SVR) which results in decreased liver-related morbidity and mortality. Prior therapies were suboptimal in co-infected patients. However, the new HCV direct-acting antiviral agents provide excellent treatment options in co-infected patients with response rates and adverse events similar to the HCV mono-infected population. Drug interactions between HIV treatments and HCV treatments can be challenging and must be taken into consideration. To optimize outcomes, co-infected patients should be managed by experienced providers or in the setting of a collaborative multidisciplinary approach. This article will review the current treatment rationale and recommendations for HIV-HCV-co-infected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34(6):831–7. doi:10.1086/339042.

    Article  PubMed  Google Scholar 

  2. Witt MD, Seaberg EC, Darilay A, Young S, Badri S, Rinaldo CR, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984–2011. Clin Infect Dis. 2013;57(1):77–84. doi:10.1093/cid/cit197.

    Article  PubMed  PubMed Central  Google Scholar 

  3. van der Helm JJ, Prins M, del Amo J, Bucher HC, Chene G, Dorrucci M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids. 2011;25(8):1083–91. doi:10.1097/QAD.0b013e3283471cce.

    Article  PubMed  Google Scholar 

  4. Fierer DS, Factor SH, Uriel AJ, Carriero DC, Dieterich DT, Mullen MP, et al. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005-2010 (reprinted from MMWR, vol 60, pg 945-950, 2011). Jama-J Am Med Assoc. 2011;306(11):1194–6.

    CAS  Google Scholar 

  5. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86(5):655–61. doi:10.2105/Ajph.86.5.655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology. 2009;137(3):795–814. doi:10.1053/j.gastro.2009.06.040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013;14(4):195–207. doi:10.1111/j.1468-1293.2012.01051.x.

    Article  CAS  PubMed  Google Scholar 

  8. Weber R. Liver-related deaths in persons infected with the human immunodeficiency virus—the D : A : D study. Arch Intern Med. 2006;166(15):1632–41. This paper describes the significantly increased risk of morbidity and mortality in patients with HIV and liver disease, especially in those with hepatitis C.

    Article  PubMed  Google Scholar 

  9. IDSA Aa. Recommendations for testing, managing, and treating hepatitis C. March, 10 2016. http://www.hcvguidelines.org/full-report-view. This website contains the AASLD/IDSA guidelines for the treatment of hepatitis C in all populations of patients. It is updated on a continuous basis by an expert panel.

  10. Lin WY, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis. 2013;207:S13–8. doi:10.1093/infdis/jis926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Macias J, Marquez M, Tellez F, Merino D, Jimenez-Aguilar P, Lopez-Cortes LF, et al. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis. 2013;57(10):1401–8. doi:10.1093/cid/cit537.

    Article  CAS  PubMed  Google Scholar 

  12. Curry MP. HIV and hepatitis C virus: special concerns for patients with cirrhosis. J Infect Dis. 2013;207:S40–4. doi:10.1093/infdis/jis763.

    Article  PubMed  Google Scholar 

  13. Chen TY, Ding EL, Seage GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49(10):1605–15. doi:10.1086/644771.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ioannou GN, Bryson CL, Weiss NS, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection: are the data found in this sample applicable to other settings? Reply. Hepatology. 2013;57(6):2545. doi:10.1002/hep.26171.

    Article  PubMed  Google Scholar 

  15. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med. 1998;338(13):853–60. doi:10.1056/Nejm199803263381301.

    Article  PubMed  Google Scholar 

  16. Swain MG, Lai MY, Shiffman ML, Cooksley WGE, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593–601. doi:10.1053/j.gastro.2010.07.009.

    Article  CAS  PubMed  Google Scholar 

  17. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–13. doi:10.1002/hep.23020.

    Article  CAS  PubMed  Google Scholar 

  18. Casado JL, Banon S, Quereda C, Moreno A, Elias MJP, Moreno S. Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver-related complications and hospital admissions in HIV/HCV co-infected patients with cirrhosis. J Int Aids Soc. 2015;18. doi:10.7448/Ias.18.5.20364. This paper demonstrates that curing hepatitis C in co-infected patients is associated with decreased liver-related complications and mortality.

  19. Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013;58(6):1104–12.

    Article  CAS  PubMed  Google Scholar 

  20. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196(5):670–6. doi:10.1086/520092.

    Article  CAS  PubMed  Google Scholar 

  21. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23(8):972–82. doi:10.1089/aid.2007.0011.

    Article  CAS  PubMed  Google Scholar 

  22. Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE, et al. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials. 2012;13(2):70–82. doi:10.1310/hct1302-70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med. 2004;351(5):438–50. doi:10.1056/NEJMoa040842.

    Article  CAS  PubMed  Google Scholar 

  24. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New Engl J Med. 2004;351(5):451–9. doi:10.1056/NEJMoa032653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients—a randomized controlled trial. Jama-J Am Med Assoc. 2004;292(23):2839–48. doi:10.1001/jama.292.23.2839.

    Article  CAS  Google Scholar 

  26. Benito JM, Sanchez-Parra C, Maida I, Aguilera A, Rallon NI, Rick F, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther. 2013;18(5):709–15. doi:10.3851/Imp2614.

    Article  CAS  PubMed  Google Scholar 

  27. Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, et al. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. Aids. 2013;27(18):2893–7. doi:10.1097/01.aids.0000432466.15885.14.

    Article  CAS  PubMed  Google Scholar 

  28. Cotte L BJ, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated interferon-ribavirin in treatment-experienced HCV genotype 1/HIV coinfected patients: ANRS HC26 TelapreVIH study. CROI 2013. Atlanta, GA. Abstract. March 3-6 2013.

  29. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis (virus genotype 1) in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597–605. doi:10.1016/S1473-3099(13)70149-X.

    Article  CAS  PubMed  Google Scholar 

  30. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) plus PegIFN/ribavirin in HCV genotype-1/HIV-1 coinfection (study C212).[Croi abstract 24] in special issue: abstracts from the 2014 conference on retroviruses and opportunistic infections. Top Antivir Med. 2014;22(e-1):34.

    Google Scholar 

  31. Sulkowski MS. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med. 2014;370(15):1469. doi:10.1056/NEJMx140017.

    CAS  Google Scholar 

  32. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. New Engl J Med. 2014;370(3):222–32. doi:10.1056/NEJMoa1306227.

    Article  CAS  PubMed  Google Scholar 

  33. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J Med. 2014;370(21):1973–82. doi:10.1056/NEJMoa1402869.

    Article  PubMed  Google Scholar 

  34. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New Engl J Med. 2014;370(21):1983–92. doi:10.1056/NEJMoa1402338.

    Article  PubMed  Google Scholar 

  35. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med. 2014;370(20):1889–98. doi:10.1056/NEJMoa1402454.

    Article  PubMed  Google Scholar 

  36. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med. 2014;370(16):1483–93. doi:10.1056/NEJMoa1316366.

    Article  CAS  PubMed  Google Scholar 

  37. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New Engl J Med. 2014;370(20):1879–88. doi:10.1056/NEJMoa1402355.

    Article  PubMed  Google Scholar 

  38. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. New Engl J Med. 2015;373(8):705–13. doi:10.1056/NEJMoa1501315. This paper showed the data from treating HIV-HCV co-infected patients with the all-oral HCV regimen of ledipasvir and sofosbuvir. The overall sustained virologic response rate for these HCV genotype 1 and 4 patients was 96 %.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Khatri A WT, Wang H et al. Drug-drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricabine + tenofovir, raltegravir, rilpivirine, and efavirenz. [Abstract 483.] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC. September 5-9,2014.

  40. Rockstroh JK, Nelson M, Katlama C. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial (vol 2, pg e319, 2015). Lancet Hiv. 2015;2(10):E416.

    Article  Google Scholar 

  41. Sulkowski MS. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection (vol 312, pg 353, 2014). Jama-J Am Med Assoc. 2014;312(18):1932.

    Google Scholar 

  42. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098–106. doi:10.1016/S0140-6736(14)62483-1.

    Article  CAS  PubMed  Google Scholar 

  43. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. New Engl J Med. 2015;373(8):714–25. doi:10.1056/NEJMoa1503153. This paper showed the data from treating HIV-HCV co-infected patients with the all-oral HCV regimen of daclatasvir and sofosbuvir. The overall sustained virologic response rate for these HCV genotype 1–4 patients was 97 %.

    Article  CAS  PubMed  Google Scholar 

  44. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New Engl J Med. 2013;368(20):1878–87. doi:10.1056/NEJMoa1214853.

    Article  CAS  PubMed  Google Scholar 

  45. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. April8, 2015;1-288. April 8, 2015. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

  46. Harvoni prescribing information http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.

  47. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama-J Am Med Assoc. 2015;313(12):1232–9. doi:10.1001/jama.2015.1373.

    Article  CAS  Google Scholar 

  48. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2015. doi:10.1002/hep.28422.

    Google Scholar 

  49. Kirby BMA, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. Boston: 63rd Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); 2012.

    Google Scholar 

  50. Sofosbuvir prescribing information http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf.

  51. German P PP, West S, et al. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. [Abstract 06.] 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC. May,19-21,2014.

  52. Garrison K CJ, Pang P, et al. Drug Interactions between anti HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens [Abstract 71]. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC. May 26-28, 2015.

  53. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;59(9):e96–138. doi:10.1093/cid/ciu617.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Viekira pak prescribing information http://www.rxabbvie.com/pdf/viekirapak_pi.pdf.

  55. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31. doi:10.1001/jama.2015.1328.

    Article  CAS  PubMed  Google Scholar 

  56. Khatri A TR, Zhao W, et al. Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine. [Abstract 57.] 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington, DC. May 26-28, 2015.

  57. Declatasvir full prescribing information http://packageinserts.bms.com/pi/pi_daklinza.pdf.

  58. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18(7):931–40. doi:10.3851/Imp2674.

    Article  CAS  PubMed  Google Scholar 

  59. Gandhi Y AR, Wang R, et al. Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir. [Abstract 80.] 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC. Mat 26-28, 2015.

  60. Song I JF, Zong J, et al. Evaluation and drug interactions between dolutegravir and daclatasvir in healthy volunteers. [Abstract 79.] 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC. May 26-28,2015.

  61. Zepatier full prescribing information https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf

  62. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38(8):E79–80. doi:10.1086/383151.

    Article  CAS  PubMed  Google Scholar 

  63. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepatitis. 2006;13(10):683–9. doi:10.1111/j.1365-2893.2006.00749.x.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    Perica Davitkov & Stanley Martin Cohen

  2. Metrohealth Medical Center, Cleveland, OH, USA

    Melissa K. Osborn

Authors
  1. Perica Davitkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa K. Osborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley Martin Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley Martin Cohen.

Ethics declarations

Conflict of Interest

PD declares that he has no conflicts of interest. MKO reports grants from and advisory board membership with Gilead, outside the submitted work. SMC reports consultancy and speaker’s bureau participation for Gilead; grants from and consultancy and speaker’s bureau participation for Bristol-Myers Squibb; and grants from and consultancy and speaker’s bureau participation for Abbvie, outside the submitted work.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and were in compliance with all applicable ethical standards.

Additional information

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davitkov, P., Osborn, M.K. & Cohen, S.M. Hepatitis C Management in Patients with Hepatitis C and HIV Co-infection. Curr Hepatology Rep 15, 158–166 (2016). https://doi.org/10.1007/s11901-016-0307-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-016-0307-9

Keywords

Search

Navigation